Caring for Melanoma Survivors with Self-Detected Concerning Moles During COVID-19 Restricted Physician Access: a Cohort Study

Main Article Content

June K Robinson
Burkhard Jansen


Melanoma, COVID-19, self-detected, moles, restricted physician access


Background: Physician appointments for non-essential care ceased during COVID-19.

Objective: To pilot test a telehealth solution for patients to rule out melanomas and need for surgical biopsies based on genomic analyses of pigmented lesion samples obtained via adhesive patches.

Methods: Surveys assessed SSE anxiety. Under remote clinician guidance, patients or partners obtained samples using adhesive patches (DermTech, La Jolla, CA).

Results: SSE anxiety increased. Guided self-sampling led to molecular risk factor analyses in 7/7 (100%) of cases compared to 9/10 (90%) randomly selected physician-sampled control cases.

Conclusions: Adhesive patch self-sampling under remote physician guidance is a viable specimen collection option.


1. Robinson JK, Wayne JD, Martini MC, Hultgren BA, Mallett KA, Turrisi R. Early detection of new melanomas by patients with melanoma and their partners using a structured skin self-examination skills training intervention: a randomized clinical trial. JAMA Dermatol. 2016;152(9):979-985.

2. President Trump Expands Telehealth Benefits for Medicare Beneficiaries During COVID-19 Outbreak. March 17, 2020.

3. de Carvalho TM, Noels E, Wakkee M, Udrea A, Nijsten T. Development of smartphone apps for skin cancer risk assessment: progress and promise. JMIR Dermatol. 2019;2 (1):e13376.

4. Gerami P, Yao S, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. J Am Acad Dermatol. 2017;76:114-20.

5. Robinson JK, Reavy R, Mallett KA, Turrisi R. Remote partner assisted skin self-examination skills training of melanoma survivors and their partners. Australian J Dermatol. 2019;60 (1):e80-82.

6. Brouha B, Ferris LK, Skelsey MK, et al. Real-world utility of a non-invasive gene expression test to rule out primary cutaneous melanoma: a large US registry study. J Drugs Dermatol. 2020 March, 19 (3).

Most read articles by the same author(s)

1 2 > >>